Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 14/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273434 | 0.94 | RET (0.44) | RETGPR119PTPN11WNT3AKDM4E | |
| SCHEMBL17273291 | 0.93 | ALK (0.45) | RETGPR119PTPN11WNT3ALMNA | |
| SCHEMBL15557190 | 0.90 | RET (0.43) | RETGPR119PTPN11WNT3AMEN1 | |
| SCHEMBL15556771 | 0.89 | GPR119 (0.48) | RETGPR119PTPN11 | |
| SCHEMBL15557586 | 0.89 | RET (0.42) | RETGPR119PTPN11WNT3AMEN1 | |
| SCHEMBL15557676 | 0.89 | PTPN11 (0.44) | RETPTPN11KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15557744 | 0.88 | RET (0.42) | RETGPR119PTPN11WNT3AMEN1 | |
| SCHEMBL17273503 | 0.88 | PTPN11 (0.43) | RETGPR119PTPN11WNT3ALMNA | |
| SCHEMBL17273295 | 0.88 | TP53 (0.42) | GPR119PTPN11LMNA | |
| SCHEMBL15555578 | 0.87 | GPR119 (0.43) | RETGPR119PTPN11WNT3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | RET 273/4885GPR119 803/4885PTPN11 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.